GW&K Investment Management LLC acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 211,127 shares of the company's stock, valued at approximately $61,488,000. GW&K Investment Management LLC owned about 0.76% of Praxis Precision Medicines as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in shares of Praxis Precision Medicines by 10.3% in the second quarter. GAMMA Investing LLC now owns 332 shares of the company's stock worth $111,000 after purchasing an additional 31 shares during the last quarter. KBC Group NV increased its stake in shares of Praxis Precision Medicines by 5.8% in the first quarter. KBC Group NV now owns 715 shares of the company's stock worth $230,000 after buying an additional 39 shares during the period. Nisa Investment Advisors LLC raised its holdings in Praxis Precision Medicines by 0.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 6,167 shares of the company's stock valued at $1,796,000 after buying an additional 56 shares during the last quarter. Ieq Capital LLC raised its holdings in Praxis Precision Medicines by 11.5% during the 3rd quarter. Ieq Capital LLC now owns 909 shares of the company's stock valued at $265,000 after buying an additional 94 shares during the last quarter. Finally, Eagle Bay Advisors LLC raised its holdings in Praxis Precision Medicines by 11.3% during the 3rd quarter. Eagle Bay Advisors LLC now owns 1,064 shares of the company's stock valued at $310,000 after buying an additional 108 shares during the last quarter. Hedge funds and other institutional investors own 67.84% of the company's stock.
Wall Street Analyst Weigh In
PRAX has been the subject of several analyst reports. Robert W. Baird increased their price target on shares of Praxis Precision Medicines from $514.00 to $568.00 and gave the company an "outperform" rating in a research report on Monday. The Goldman Sachs Group restated a "buy" rating and issued a $575.00 price objective (up from $470.00) on shares of Praxis Precision Medicines in a research report on Friday, August 21st. BTIG Research reaffirmed a "buy" rating and set a $826.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, November 9th. Wells Fargo & Company set a $509.00 price objective on shares of Praxis Precision Medicines and gave the company an "overweight" rating in a research note on Tuesday. Finally, Royal Bank Of Canada increased their target price on shares of Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an "outperform" rating in a report on Tuesday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Praxis Precision Medicines currently has a consensus rating of "Moderate Buy" and an average price target of $656.42.
Read Our Latest Stock Analysis on PRAX
Praxis Precision Medicines Trading Up 1.9%
Shares of PRAX stock opened at $310.90 on Friday. Praxis Precision Medicines, Inc. has a 12 month low of $160.11 and a 12 month high of $392.70. The stock has a market cap of $8.69 billion, a PE ratio of -24.29 and a beta of 2.85. The company's fifty day moving average price is $286.77 and its 200-day moving average price is $314.30.
Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($3.23) earnings per share for the quarter, topping analysts' consensus estimates of ($3.54) by $0.31. On average, sell-side analysts forecast that Praxis Precision Medicines, Inc. will post -13.72 earnings per share for the current fiscal year.
Praxis Precision Medicines Profile
(
Free Report)
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.